Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ.

Mod Pathol. 2007 May;20(5):584-91. Epub 2007 Mar 30.

2.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

3.

Concordance between central and local laboratory HER2 testing from a community-based clinical study.

Reddy JC, Reimann JD, Anderson SM, Klein PM.

Clin Breast Cancer. 2006 Jun;7(2):153-7.

PMID:
16800975
4.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
5.

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB.

J Clin Oncol. 2006 Jul 1;24(19):3032-8.

PMID:
16809727
6.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

7.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group.

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

8.

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

Garrison LP Jr, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA.

Cancer. 2013 Sep 1;119(17):3113-22. doi: 10.1002/cncr.28196. Epub 2013 Jun 17.

9.

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE.

J Pathol. 2003 Apr;199(4):418-23.

PMID:
12635131
10.

Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.

Ogura H, Akiyama F, Kasumi F, Kazui T, Sakamoto G.

Breast Cancer. 2003;10(3):234-40.

PMID:
12955036
11.

HER-2 testing in breast cancer using parallel tissue-based methods.

Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM.

JAMA. 2004 Apr 28;291(16):1972-7.

PMID:
15113815
12.

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.

Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY.

BMC Cancer. 2010 Oct 7;10:534. doi: 10.1186/1471-2407-10-534.

13.

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.

Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J.

J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.

PMID:
17412870
14.

Maximizing the response to Herceptin therapy through optimal use and patient selection.

Leyland-Jones B.

Anticancer Drugs. 2001 Dec;12 Suppl 4:S11-7. Review.

PMID:
11989522
15.

What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.

Umemura S, Osamura RY, Akiyama F, Honma K, Kurosumi M, Sasano H, Toyoshima S, Tsuda H, Rüschoff J, Sakamoto G.

Am J Clin Pathol. 2008 Dec;130(6):883-91. doi: 10.1309/AJCP5UUMFMA5ZKII.

PMID:
19019764
16.

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T.

Arch Pathol Lab Med. 2008 Jan;132(1):61-5. doi: 10.1043/1543-2165(2008)132[61:HTIAPS]2.0.CO;2. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne].

PMID:
18181675
17.

[Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].

Fernö M, Haglund M, Bendahl PO, Olsson H, Rydén L.

Lakartidningen. 2008 Aug 6-19;105(32-33):2181-4. Swedish. No abstract available.

PMID:
18780693
18.

Comparison of HER2 detection methods between central and regional laboratories in Greece.

Papadopoulos S, Kouvatseas G, Skarlos D, Malamos N, Delliou E, Saratsiotou I, Ardavanis A, Mavroudis D, Skarpidi E, Arapantoni P, Karyda I, Patakioyta F, Aravantinos G, Razis E, Fountzilas G, Kosmidis P.

Clin Breast Cancer. 2007 Oct;7(10):784-90.

PMID:
18021480
19.

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.

Hicks DG, Kulkarni S.

Am J Clin Pathol. 2008 Feb;129(2):263-73. doi: 10.1309/99AE032R9FM8WND1. Review.

PMID:
18208807
20.

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S, Loening T, Pantel K.

J Cancer Res Clin Oncol. 2011 Feb;137(2):261-9. doi: 10.1007/s00432-010-0881-0. Epub 2010 Apr 16.

PMID:
20396915

Supplemental Content

Support Center